Advertisement

Topics

Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 Pipeline Review, H1 2017

Summary

Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 pipeline Target constitutes close to 39 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.

Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 Bromodomaincontaining protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser2 of the Cterminal domain CTD of RNA polymerase II. It acts as a regulator of p53/TP53mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 21 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders, Ophthalmology and Respiratory which include indications Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Solid Tumor, Multiple Myeloma Kahler Disease, Breast Cancer, Myelodysplastic Syndrome, Diffuse Large BCell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Hematological Tumor, Inflammation, NUT Midline Carcinoma NMC or Nuclear Protein in Testis Midline Carcinoma, Ovarian Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Atherosclerosis, Colorectal Cancer, Lymphoma, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, NonSmall Cell Lung Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Alzheimer's Disease, BCell NonHodgkin Lymphoma, Blood Cancer, Burkitt Lymphoma, Carcinomas, Chronic Kidney Disease Chronic Renal Failure, Chronic Lymphocytic Leukemia CLL, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Coronary Artery Disease CAD Ischemic Heart Disease, Fabry Disease, Follicular Lymphoma, Glioblastoma Multiforme GBM, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Brain Tumor, Metastatic Liver Cancer, Nephropathy, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease PAD/ Peripheral Vascular Disease PVD, Peripheral Nerve Sheath Tumor Neurofibrosarcoma, PreDiabetes/Impaired Glucose Tolerance, Renal Cell Carcinoma, Retinal Degeneration, Rheumatoid Arthritis, SmallCell Lung Cancer, Substance Drug Abuse and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 Protein HUNK1 or BRD4
The report reviews Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 targeted therapeutics and enlists all their major and minor projects
The report assesses Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 Protein HUNK1 or BRD4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Bromodomain Containing Protein 4 Protein HUNK1 or BRD4 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...